19
Jan
2009
Posted in I - Series E, Q - 1Q09, R - INTERNATIONAL, X - Cardiology, X - Metabolism, X - Obesity
7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, Credit Agricole Private Equity, GIMV and BioMedinvest.